Evidence map›Paper›PMID 38407670›Full record

ReviewDiscover nano2024

Theranostics: a multifaceted approach utilizing nano-biomaterials.

Mohammad Yasir, Ratnakar Mishra, Alok Shiomurti Tripathi, Rahul K Maurya, Ashutosh Shahi, Magdi E A Zaki, Sami A Al Hussain, Vijay H Masand

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Smart nanoplatforms for early detection and immune modulation in lung cancer.Frontiers in bioengineering and biotechnology · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohammad YasirAmity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector125, Noida, 201313, India. yasirmohammad6@gmail.com.
Ratnakar MishraAmity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector125, Noida, 201313, India.
Alok Shiomurti TripathiEra College of Pharmacy, Era University, Lucknow, 226003, India.
Rahul K MauryaAmity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector125, Noida, 201313, India.
Ashutosh ShahiAmity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector125, Noida, 201313, India.
Magdi E A ZakiDepartment of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University, Riyadh, 13318, Saudi Arabia. mezaki@imamu.edu.sa.
Sami A Al HussainDepartment of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University, Riyadh, 13318, Saudi Arabia.
Vijay H MasandDepartment of Chemistry, Vidya Bharati Mahavidyalaya, Amravati, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomaterials play a vital role in targeting therapeutics. Over the years, several biomaterials have gained wide attention in the treatment and diagnosis of diseases. Scientists are trying to make more personalized treatments for different diseases, as well as discovering novel single agents that can be used for prognosis, medication administration, and keeping track of how a treatment works. Theranostics based on nano-biomaterials have higher sensitivity and specificity for disease management than conventional techniques. This review provides a concise overview of various biomaterials, including carbon-based materials like fullerenes, graphene, carbon nanotubes (CNTs), and carbon nanofibers, and their involvement in theranostics of different diseases. In addition, the involvement of imaging techniques for theranostics applications was overviewed. Theranostics is an emerging strategy that has great potential for enhancing the accuracy and efficacy of medicinal interventions. Despite the presence of obstacles such as disease heterogeneity, toxicity, reproducibility, uniformity, upscaling production, and regulatory hurdles, the field of medical research and development has great promise due to its ability to provide patients with personalised care, facilitate early identification, and enable focused treatment.

Indexed as

BiomaterialsCarbon based materialsCarriers of biomaterialsImaging modalitiesTheranostics

Identifiers

PMID38407670
PMCPMC10897124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.